Validus Recalls Calcitriol Oral Solution Due to Subpotency
Validus Pharmaceuticals is recalling 7,864 bottles of Calcitriol Oral Solution because testing showed lower than expected potency at the 18-month stability time point.
The agency’s classification
FDA (Drugs): Class III
Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which is defined as unlikely to cause adverse health consequences. The hazard is subpotency (reduced effectiveness) rather than toxicity or contamination, fitting the Moderate severity criteria for low-risk quality issues.
Plain-English summary
Validus Pharmaceuticals, Inc. is recalling 7,864 bottles of Calcitriol Oral Solution, 1 mcg/mL, 15 mL bottle, Rx Only. The product is distributed by Ranbaxy Pharmaceuticals Inc. in Jacksonville, FL, and carries NDC 63304-241-59. The affected lots are RV1602RB (Exp 07/2019), RV1604RB (Exp 9/2019), and RV1605RB (Exp 10/2019).
The recall was initiated because a lower than expected potency result was obtained at the 18-month stability time point. This indicates the medication may not be as strong as labeled, potentially reducing its effectiveness for patients.
The product was distributed nationwide in the U.S. Patients and healthcare providers should stop using the affected bottles and contact their healthcare provider or pharmacist for guidance on replacement or alternative treatment.
The recalled product
- Product
- Calcitriol Oral Solution, 1 mcg/mL, 15 mL bottle, Rx Only, Distributed by: Ranbaxy Pharmaceuticals Inc. Jacksonville, FL 32257 USA, NDC 63304-241-59
- Manufacturer
- Validus Pharmaceuticals, Inc.
- Category
- Drug — Oral Solution
- Hazard
- Affected units
- 7,864
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- RV1602RB
- Exp 07/2019
- RV1604RB
- Exp 9/2019
- RV1605RB
- Exp 10/2019
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Validus Pharmaceuticals, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Validus Pharmaceuticals, Inc.
See all →- LowValidus Recalls Rocaltrol Oral Solution Due to Lower Potency
FDA (Drugs) · 2018-09-05
Same hazard · subpotency
See all →- ModerateGood Neighbor Pharmacy Earwax Removal Drug Recalled for Low Potency
FDA (Drugs) · 2026-07-22
- ModerateNystatin Cream Recall Due to Low Potency Test Results
FDA (Drugs) · 2026-07-22
- ModerateFoster & Thrive Carbamide Peroxide 6.5% Recalled for Subpotent Strength
FDA (Drugs) · 2026-07-22
- ModerateLeader Carbamide Peroxide Earwax Removal Kit Recalled for Subpotency
FDA (Drugs) · 2026-07-22
- ModerateMeijer Earwax Removal Kit Recalled for Subpotent Active Ingredient
FDA (Drugs) · 2026-07-22
Similar recalls
- SevereBoehringer Ingelheim Roxane Recalls Calcitriol Oral Solution Due to Impurity
FDA (Drugs) · 2014-07-16
- ModerateHi-Tech Pharmacal Recalls Subpotent HydrOXYzine Hydrochloride Oral Solution
FDA (Drugs) · 2013-06-26
- LowApotex Recalls Risperidone Oral Solution Due to Impurity Specification Failure
FDA (Drugs) · 2014-05-07
- HighLevothyroxine Sodium Tablets recalled nationwide for potency failures
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled Due to Potency Failures
FDA (Drugs) · 2024-12-18
- LowHi-Tech Pharmacal Recalls Acyclovir Oral Suspension for Stability Failures
FDA (Drugs) · 2014-01-01